N/A N=37 A Unified Treatment for Anxiety Disorders
Emotional Disorders · Anxiety Disorders
Primary: Anxiety Disorders Interview Schedule for DSM-IV — 5.23; 5.09; 3.18; 5.14 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=918 Expectation of Unpleasant Events in Anxiety Disorders
Anxiety Disorders
Primary: Change in Percent of Correct Button Presses During Threat Compared to the Safe Condition (AAST) — -0.016; 0.008 Percentage of accurate responses
Phase 4 N=89 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
N/A N=167 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
Autism Spectrum Disorders · Autism · Asperger's Syndrome
Primary: Change From Baseline in Anxiety Severity on the Pediatric Anxiety Rating Scale After 16 Weeks of Treatment. — 3.43; 3.47; 3.28; 2.13 units on a scale
Phase 3 N=30 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Autism Spectrum Disorders
Primary: Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase — -4.9; -3.2 score on a scale
Phase 2 N=89 Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Primary: Change in Ventral Striatal Activation Occurring in Anticipation of Reward During the Monetary Incentive Delay Task Measured by fMRI — 0.718; 0.331 Z score — p=0.0095
Phase 4 N=60 Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Anxiety Disorder
Primary: Magnitude of Startle Reflex During Safe Condition — 42.2880893; 42.39801; 43.61243; 44.1886408 millivolts (mV)
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
Phase 3 N=81 Psychosocial and Medication Treatment for Anxiety in Alcoholism
Alcohol-Related Disorders · Anxiety Disorders
Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale
Phase 2 N=33 Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale. — 11.62; 14.04 units on a scale — p=.04
N/A N=56 Anxiety in Older Veterans
Anxiety Disorders
Primary: Change in Anxiety Symptoms — 1.77; -2.42 units on a scale
N/A N=15 Assessing Visual Processing in High Anxiety
Anxiety
Primary: Tolerability of the Micro Expression Training Task in Individuals With High Anxiety — 5; 6 Participants
N/A N=128 Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
Anxiety · Cardiovascular Disease
Primary: Change in Hospital Anxiety and Depression Scale (HADS), Anxiety — -3.9; -5.7; -3.5 score on a scale — p=0.038
N/A N=29 Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder
Bipolar Disorder · Anxiety Disorders
Primary: Reductions Over Time in Anxiety Symptoms as Measured by Hamilton Anxiety Rating Scale — 14; 18.81; 11.78; 17.70 Units on scale — p=.02
N/A N=68 Effect of rTMS on Anxiety
Anxiety · Fear · Anxiety and Fear
Primary: Anxiety Potentiated Startle — 4.600026484; 3.411297242; 3.122643391; 4.848463905 T-scores
Phase 4 N=1,004 Primary Care Intervention Strategy for Anxiety Disorders
Post-traumatic Stress Disorder · Generalized Anxiety Disorder · Panic Disorder
Primary: BSI-12 (Anxiety and Somatization Subscales) — 325; 258 number of responders
N/A N=93 Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
Major Depressive Disorder · Persistent Depressive Disorder · Posttraumatic Stress Disorder
Primary: DASS-Depression — 3.93; 5.91; 4.51; 6.01 score on a scale
N/A N=188 Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
Tobacco Dependence
Primary: Plasma Cotinine Concentration — 82.8; 259.0 ng/mL — p=<0.0001
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
Phase 2 N=41 PH94B in the Treatment of Adjustment Disorder With Anxiety
Adjustment Disorder With Anxious Mood
Primary: Hamilton Anxiety Scale (HAM-A) Score — -12.5; -12.6 score on a scale — p=0.9338
Phase 4 N=32 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
Generalized Anxiety Disorder
Primary: Signal Change in Brain Activity in the Amygdala When Viewing Emotional Faces — .1489; .1074; .0119; .1404 Percent signal change in brain acitivity
N/A N=31 Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Autism · Asperger's Syndrome · Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale — 10.94; 13.93 units on a scale
N/A N=1,418 Effects of Arousal and Stress in Anxiety
Healthy Volunteers
Primary: Go Correct Hits Followed by Button Press — 90.9; 91.6 Percentage of correct responses
N/A N=18 Novel Anxiety Treatment
Cognitive Training · Anxiety Disorders
Primary: Change in Symptoms of Anxiety Based on Screen for Anxiety and Related Disorders (SCARED) Parent Report at Baseline and Post Assessment — -20.4; -21.12 units on a scale
Phase 2 N=24 Treatment of Anxiety and Anorexia Nervosa in Adolescents
Anxiety · Anorexia Nervosa
Primary: Medication Side Effects Score — 9.5; 6.2; 6.4; 4.1 Score on a scale
N/A N=27 Strategies for Treating Anxiety Research Study
Anxiety Disorders · Anxiety
Primary: Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. — 17 Participants
N/A N=50 Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety
Depression · Anxiety
Primary: Number of Participants Meeting Depression Remission Criteria — 10; 15 participants
N/A N=51 Identifying Decision Making Parameters in Healthy Volunteers and Anxiety Patients
Anxiety · Healthy Volunteers
Primary: Difference in Learning Rate — 0.009; 0.0058 unitless
Phase 3 N=45 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
Autism · Asperger's Syndrome · Generalized Anxiety Disorder
Primary: Pediatric Anxiety Rating Scale (Measures the Severity of Anxiety Symptoms) — 16.33; 17.62; 11.58; 16.05 units on a scale
Phase 3 N=265 Transdiagnostic Cognitive Behavioral Treatment for Anxiety
Anxiety Disorders
Primary: CRIS-EPS: Comparison of Extent of Participation Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups — 4.21; 4.18; 4.17; 4.52 score on a…